{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/obsessive-compulsive-disorder/prescribing-information/ssris/","result":{"pageContext":{"chapter":{"id":"0b63ad08-27a9-5af8-8fb8-6940aa3d3dc3","slug":"ssris","fullItemName":"SSRIs","depth":2,"htmlHeader":"<!-- begin field f621f2c9-05b0-4443-bf0d-a91100c4b9d7 --><h2>SSRIs</h2><!-- end field f621f2c9-05b0-4443-bf0d-a91100c4b9d7 -->","summary":"","htmlStringContent":"<!-- begin item d51cb228-e67e-4186-9f6f-a91100c4b6cc --><!-- end item d51cb228-e67e-4186-9f6f-a91100c4b6cc -->","topic":{"id":"1f37cc0e-7573-58d0-a414-18973c123eae","topicId":"394f419d-3ab3-4fd3-85c7-7ae0c286d323","topicName":"Obsessive-compulsive disorder","slug":"obsessive-compulsive-disorder","lastRevised":"Last revised in June 2018","chapters":[{"id":"6854ef67-5e05-528c-afeb-b7680f464892","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"0151ee13-83cc-5d06-9ce4-f03bc14a2d91","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a6ac8f0f-9ef4-5778-82e7-0ee23afbaaf8","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f571042f-c058-5f39-a22d-6901a3f9f4d0","slug":"changes","fullItemName":"Changes"},{"id":"31a9215e-18d0-5bd1-9341-846c7185dd16","slug":"update","fullItemName":"Update"}]},{"id":"39a21515-e7bc-515d-80d4-420f429a801f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"9c01874c-054d-55f7-bc72-c5dc572bb4ce","slug":"goals","fullItemName":"Goals"},{"id":"bb1af94d-3d5a-5862-9e75-51cfd39e9e31","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"31dd33b1-cd86-57bc-84c1-206363cae677","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8aa2028a-8646-59f5-ac0b-c585d5f9474a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"96f32bee-6f1f-5862-8163-8f9adf02e81e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0c41f244-6591-5043-825b-f48000a19060","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"69296d43-e92e-51ad-803f-9b00dd4ef3eb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"23304d59-7975-500a-9672-1d71c224d42b","slug":"definition","fullItemName":"Definition"},{"id":"75facf2a-3aa9-52ec-a213-c09d7c49305a","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ef703cf4-f71d-53e8-ac6e-55fd3949af89","slug":"prevalence","fullItemName":"Prevalence"},{"id":"16615ebe-7c11-54ea-8c8f-11b27bd84df0","slug":"prognosis","fullItemName":"Prognosis"},{"id":"9c3a46c7-846c-5e14-9297-e80dfc82ffa5","slug":"complications","fullItemName":"Complications"}]},{"id":"9063127c-d315-5f06-81a4-0854a79730a5","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8e2a1f2f-09ef-5f73-a3ec-2aac2b0a90b7","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"d07d5382-3d58-534c-80b0-ebb514c9d790","fullItemName":"Management","slug":"management","subChapters":[{"id":"adfa1e25-924b-5e4d-b909-bbd62bfa3981","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"1a83f73e-9ca7-5f30-9cda-aaa563048a36","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"0b63ad08-27a9-5af8-8fb8-6940aa3d3dc3","slug":"ssris","fullItemName":"SSRIs"},{"id":"32401b30-535f-57bf-8154-4e5efa0884e3","slug":"clomipramine","fullItemName":"Clomipramine"}]},{"id":"34094942-974d-50ae-b83e-52a2243c1e47","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[{"id":"06ebd4e9-a6ff-5645-8bf1-4a06d03e073b","slug":"psychological-treatments-in-adults","fullItemName":"Psychological treatments in adults"},{"id":"73a36a4c-8f66-5d63-a4ad-c1667bd42f3b","slug":"ssris-in-adults","fullItemName":"SSRIs in adults"},{"id":"f077f54e-c77f-533b-84b3-6f81c9eb4f89","slug":"pharmacological-versus-psychological-treatments-in-adults","fullItemName":"Pharmacological versus psychological treatments in adults"},{"id":"d63bb159-7b2d-54b3-a251-0fb81b09618f","slug":"combination-treatments-in-adults","fullItemName":"Combination treatments in adults"}]},{"id":"ed477751-4d36-5e3b-bfcb-60739e1daea7","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6e26607d-6208-5c71-a5ee-ba2bd8567311","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"700ff2f4-6d6b-5235-8301-91ad6701f206","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"20682403-8c70-5f97-86c4-1f8234b42261","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"9242ca74-0efb-54f8-9cb4-267acc46dc6c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"8a264e61-1997-5859-8b1d-e1d859ffa219","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c91ccb0b-b8e6-5c2a-ab14-79b9eff3e63a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1a83f73e-9ca7-5f30-9cda-aaa563048a36","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"eaaf2c7e-45c3-5064-8124-b07746eb3ac1","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 40d5810a-7604-425e-82c6-a91100c4ef46 --><h3>Contraindications and cautions</h3><!-- end field 40d5810a-7604-425e-82c6-a91100c4ef46 -->","summary":"","htmlStringContent":"<!-- begin item d8020ff2-d117-48a7-b734-a91100c4edd9 --><!-- begin field 7b416e99-1215-4183-ba37-a91100c4ef46 --><ul><li><strong>Do not prescribe SSRIs to people:</strong><ul><li>In a manic phase of bipolar disorder.</li><li>Taking monoamine oxidase inhibitors (MAOIs), or who have recently discontinued a MAOI.</li><li>Taking pimozide.</li><li>With uncontrolled epilepsy or new onset seizures.</li></ul></li><li><strong>Do not prescribe citalopram to people with:</strong><ul><li>Known QT-interval prolongation or congenital long QT syndrome, or those using other medicinal products that are known to prolong the QT-interval.</li><li>Severe renal impairment (creatinine clearance less than 20 ml/min).</li></ul></li><li><strong>Do not prescribe escitalopram to people with:</strong><ul><li>Known QT interval prolongation, or taking medication known to prolong the QT interval.</li><li>Congenital long QT syndrome.</li></ul></li><li><strong>Do not prescribe fluoxetine or paroxetine in combination with metoprolol.</strong></li><li><strong>Do not precribe fluvoxamine in combination with tizanidine, terfenadine, astemizole, or cisapride.</strong></li><li><strong>Do not prescribe paroxetine in combination with </strong><strong>thioridazine</strong> — this can elevate plasma levels of thioridazine, increasing the risk of QTc interval prolongation with associated serious ventricular arrhythmia such as torsades de pointes, and sudden death.</li><li><strong>Do not prescribe sertraline to people with severe hepatic impairment.</strong></li><li><strong>Prescribe SSRIs with caution to people with:</strong><ul><li>Cardiac disease.</li><li>Risk factors for QTc prolongation such as congenital long QT syndrome, a family history of QT prolongation or other clinical conditions that predispose to arrhythmias (e.g., hypokalemia and hypomagnesemia, bradycardia, acute myocardial infarction or uncompensated heart failure), or concomitant use with medicinal products known to induce hypokalemia and hypomagnesemia, QT prolongation, and/or torsade de pointes — cases of QT interval prolongation and ventricular arrhythmia including torsade de pointes have been reported during the post-marketing period. If signs of cardiac arrhythmia occur during treatment with an SSRI, the treatment should be withdrawn and an ECG should be performed. (Note: citalopram is contraindicated in these groups, see above).</li><li>Epilepsy (discontinue if convulsions develop).</li><li>A history of bleeding disorders, especially gastrointestinal bleeding.<ul><li>Older people or people taking drugs that can damage the gastrointestinal mucosa or interfere with clotting (for example, NSAIDS or aspirin) may also be at risk. Consider prescribing a gastroprotective drug in these circumstances.</li></ul></li><li>Diabetes mellitus.</li><li>History of mania.</li><li>Susceptibility to angle-closure glaucoma.</li><li>Also, prescribe with caution to those undergoing concurrent electroconvulsive therapy.</li></ul></li><li><strong>Prescribe fluoxetine and citalopram, and sertraline with caution to people with hepatic impairment</strong> — a lower or less frequent dose should be considered and liver function should be closely monitored.</li><li><strong>Prescribe fluvoxamine and paroxetine with caution to people with hepatic or renal impairment </strong>— prescribe a low starting dose and monitor carefully.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2017d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2017e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2017f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">BNF 75, 2018</a>]</p><!-- end field 7b416e99-1215-4183-ba37-a91100c4ef46 --><!-- end item d8020ff2-d117-48a7-b734-a91100c4edd9 -->","subChapters":[]},{"id":"3dbfae7a-8642-580d-93af-5e00c24ffd62","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field d9d201ba-e7ca-4e40-a9ab-a91100c50627 --><h3>Adverse effects</h3><!-- end field d9d201ba-e7ca-4e40-a9ab-a91100c50627 -->","summary":"","htmlStringContent":"<!-- begin item 71870c95-2cf8-4117-9766-a91100c504b9 --><!-- begin field 3ff1a56c-4fc6-4165-a328-a91100c50627 --><ul><li><strong>The most common adverse effects associated with use of an SSRI are:</strong><ul><li><strong>Gastrointestinal effects</strong> — these are dose-related and include nausea, vomiting, abdominal pain, dyspepsia, constipation, and diarrhoea.</li><li><strong>Central nervous system effects </strong>— including dizziness, agitation, anxiety, insomnia, headache, and tremor.</li><li><strong>Akathisia </strong>— characterised by a subjectively unpleasant or distressing restlessness and need to move often accompanied by an inability to sit or stand still. This is most likely to occur within the first few weeks of treatment. In people who develop these symptoms, increasing the dose may be detrimental.</li><li><strong>Drowsiness</strong> — may impair performance of skilled tasks such as driving and operating machinery.<ul><li>Advise the person that it is illegal in England and Wales to drive while taking a prescribed drug if it impairs driving [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">DVLA, 2015a</a>].</li></ul></li><li><strong>Sexual dysfunction </strong>— which may persist after discontinuation. </li></ul></li><li><strong>Other adverse effects include:</strong><ul><li><strong>Increased risk of bleeding,</strong> especially in older people or people taking other drugs that can damage the gastrointestinal mucosa or interfere with clotting (for example, nonsteroidal anti-inflammatory drugs [NSAIDs]).</li><li><strong>Increased risk of fractures</strong> — the Medicines and Healthcare products Regulatory Agency (MHRA) has advised that SSRIs are associated with a small increased risk of fractures; however, the mechanism leading to this is unclear and may be multifactorial. </li><li><strong>Hyponatraemia</strong> — risk factors for developing hyponatraemia include a history of hyponatraemia, extreme old age (greater than 80 years of age), female sex, low body weight, diuretics, diabetes mellitus, hypertension, reduced renal function, volume depletion, and chronic obstructive pulmonary disease.<ul><li>Monitor the person for signs and symptoms of hyponatraemia (such as dizziness, lethargy, nausea, confusion, cramps, and seizures).</li></ul></li><li><strong>Increased suicide risk</strong> — this is most likely in younger people (less than 30 years of age) when starting an SSRI.<ul><li>Monitor people carefully during the first few weeks of SSRI treatment; in particular, be alert for signs of suicidal ideation, akathisia, and increased anxiety and agitation. For more information on monitoring suicide risk, see the section on 'assessing suicide risk' in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a>.</li></ul></li><li><strong>Discontinuation symptoms</strong> (such as dizziness, sensory disturbances [including paraesthesia], sleep disturbances [including insomnia and intense dreams], agitation or anxiety, nausea and/or vomiting, tremor, and headache).<ul><li>The risk of discontinuation symptoms may be dependent on several factors including the duration and dose of therapy and the rate of dose reduction. </li><li>Generally these symptoms are mild to moderate; however, in some people, they may be severe.</li><li>They usually occur within the first few days of discontinuing treatment.</li><li>Generally, these symptoms are self-limiting and usually resolve within 2 weeks, though in some individuals they may be prolonged (2 – 3 months or more).</li><li>It is therefore advised that an SSRI should be gradually tapered over a period of several weeks or months, according to the person's needs.</li><li>Paroxetine is associated with a higher incidence of discontinuation symptoms compared with other selective serotonin reuptake inhibitors.</li></ul></li><li><strong>For citalopram and escitalopram, QT prolongation and/or ventricular arrhythmias</strong>; especially in women, people with hypokalaemia, or people with pre-existing QT prolongation or other cardiac disease.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">MHRA, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2017d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2017e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2017f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">BNF 75, 2018</a>]</p><!-- end field 3ff1a56c-4fc6-4165-a328-a91100c50627 --><!-- end item 71870c95-2cf8-4117-9766-a91100c504b9 -->","subChapters":[]},{"id":"c7674615-93cb-53bb-8a22-5444257dfa31","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 84dd4692-cb61-41d0-9b9e-a91100c51cdb --><h3>Drug interactions</h3><!-- end field 84dd4692-cb61-41d0-9b9e-a91100c51cdb -->","summary":"","htmlStringContent":"<!-- begin item 9b291b2f-7bd2-47a0-862d-a91100c51ad3 --><!-- begin field 1f2e71d9-7e40-460e-9dc9-a91100c51cdb --><p><strong>Key drug interactions with SSRIs as a class include:</strong></p><ul><li>5HT<sub>3</sub> receptor antagonists, dapoxetine, duloxetine, fentanyl, Rasagiline, St John's Wort, tramadol, triptans — increased risk of serotonergic effects.<ul><li>The manufacturer of dapoxetine advises SSRIs should not be started until 1 week after stopping dapoxetine, and to avoid dapoxetine for 2 weeks after stopping SSRIs.</li></ul></li><li>Antiepileptics — SSRIs antagonise anticonvulsant effect of antiepileptics (convulsive threshold lowered).</li><li>Aspirin, dabigatran, and NSAIDs — increased risk of bleeding.</li><li>Coumarins — SSRIs possibly enhance anticoagulant effect of coumarins.<ul><li>Consider frequent monitoring of the INR. Any change in the person's clinical condition, particularly liver disease, intercurrent illness, or drug administration, necessitates more frequent monitoring of the INR. </li></ul></li><li>Cyproheptadine — antidepressant effect of SSRIs possibly antagonised by cyproheptadine.</li><li>Lithium — increased risk of CNS effects when SSRIs given with lithium (lithium toxicity reported).<ul><li>Advise the person be alert for symptoms such as decreased appetite, diarrhoea, vomiting, ataxia, nystagmus, dysarthria, confusion, and seizures. Consider frequent monitoring of lithium levels.</li></ul></li><li>MAOIs — CNS effects of SSRIs increased by MAOIs (risk of serious toxicity).</li><li>Methylphenidate — metabolism of SSRIs possibly inhibited.</li><li>Pimozide — SSRIs possibly increase plasma concentration of pimozide (increased risk of ventricular arrhythmias—avoid concomitant use).</li><li>Ritonavir — plasma concentration of SSRIs possibly increased.</li><li>Tricyclic antidepressants — SSRIs increase plasma concentration of some tricyclics</li><li>Vortioxetine — possible increased risk of convulsions.</li></ul><p><strong>Key drug interactions with specific SSRIs include:</strong></p><ul><li><strong>Citalopram and escitalopram</strong><ul><li>Linezolid — avoid co-administration unless there are facilities for close observation and monitoring of blood pressure.</li><li>Drugs that prolong the QT interval (such as Class IA and III antiarrhythmics, antipsychotics [phenothiazine derivatives, pimozide, haloperidol], tricyclic antidepressants, certain antimicrobial agents [sparfloxacin, moxifloxacin, erythromycin IV, pentamidine], anti-malaria treatment particularly halofantrine, certain antihistamines [astemizole, mizolastine], and antiretrovirals [such as ritonavir, saquinavir, and lopinavir].</li><li>Fluconazole — the manufacturer advises that concomitant use should only be undertaken when necessary and with caution. </li><li>Selegiline — the concomitant use of citalopram and selegiline (in doses above 10mg daily) is contraindicated.</li><li>Omeprazole, esomeprazole, fluvoxamine, lansoprazole, ticlopidine, and cimetidine — co-administration can cause an increase in the average steady-state levels of citalopram. Dose adjustment may be warranted.</li><li>Propafenone, flecainide, metoprolol, desipramine, clomipramine, nortriptyline, risperidone, thioridazine and haloperidol — co-administration may lead to increased plasma levels of these drugs.</li></ul></li><li><strong>Fluoxetine:</strong><ul><li>Mequitazine — increased risk of mequitazine adverse events (such as QT prolongation) because of an inhibition of its metabolism by fluoxetine.</li><li>Metoprolol used in cardiac failure — increased risk of metoprolol adverse events including excessive bradycardia, because of inhibition of its metabolism by fluoxetine.</li><li>Drugs that cause QT interval prolongation (such as Class IA and III antiarrhythmics, antipsychotics [phenothiazine derivatives, pimozide, haloperidol], tricyclic antidepressants, certain antimicrobial agents [sparfloxacin, moxifloxacin, erythromycin IV, pentamidine], anti-malaria treatment particularly halofantrine, certain antihistamines [astemizole, mizolastine], and antiretrovirals [such as ritonavir, saquinavir, and lopinavir] — pharmacokinetic and pharmacodynamic studies with fluoxetine have not been performed. An additive effect of fluoxetine and these medicinal products cannot be excluded. </li><li>Phenytoin — changes in blood levels (and in some cases, toxicity) have been observed in combination with fluoxetine — consider using conservative titration schedules and to monitor clinical status.</li><li>Drugs that cause hyponatraemia such as diuretics, desmopressin, carbamazepine and oxcarbazepine, as fluoxetine also causes hyponatraemia.</li><li>Procyclidine — daily administration of paroxetine increases significantly its plasma levels. If anticholinergic effects are seen, the dose of procyclidine should be reduced.</li></ul></li><li><strong>Fluvoxamine:</strong><ul><li>Terfenadine, astemizole or cisapride — plasma concentrations may be increased resulting in a higher risk for QT-prolongation/Torsade de Pointes.</li><li>Tizanidine.</li><li>Tacrine, theophylline, methadone, mexiletine, phenytoin, carbamazepine and cyclosporine — co-administration with fluvoxamine should be carefully monitored.</li><li>Triazolam, midazolam, alprazolam, and diazepam — plasma levels are likely to be increased when co-administered with fluvoxamine. The dosage of these benzodiazepines should, therefore, be reduced during co-administration.</li><li>Ropinirole — plasma concentrations may be increased in combination with fluvoxamine, thus increasing the risk of overdose. Surveillance and reduction in the dosage of ropinirole during fluvoxamine treatment and after its withdrawal may, therefore, be required.</li><li>Propranolol — as plasma concentrations of are increased in combination with fluvoxamine, the propranolol dose may need to be lowered.</li></ul></li><li><strong>Paroxetine:</strong><ul><li>Metoprolol — increased risk of metoprolol adverse events because of inhibition of its metabolism by paroxetine.</li><li>Tamoxifen — paroxetine is a potent inhibitor of the liver enzyme CYP2D6 and may reduce the plasma concentration of tamoxifen, leading to reduced efficacy.</li><li>Thioridazine —  this can lead to elevated plasma levels of thioridazine and increased risk of QTc interval prolongation with associated serious ventricular arrhythmia such as torsades de pointes, and sudden death.</li><li>Aripiprazole, clozapine, darifenacin, galantamine, methadone, metoprolol, pitolisant, procyclidine, ranolazine, risperidone and vortioxetine — paroxetine may increase their plasma concentrations.</li><li>Atomoxetine, perphenazine, and propafenone — paroxetine may inhibit their metabolism.</li><li>Asenapine, darunavir, fosphenytoin, phenobarbital, phenytoin, primidone, ritonavir, and terbinafine — may alter plasma concentration of paroxetine.</li><li>Sumatriptan — there is an increased risk of CNS toxicity when given with paroxetine.</li><li>Pravastatin — co-administration may lead to an increase in blood glucose levels. People with diabetes mellitus receiving both drugs may require dosage adjustment of oral hypoglycemic agents and/or insulin. </li></ul></li><li><strong>Sertraline</strong><ul><li>Propafenone and flecainide — co-administration may lead to increased plasma levels of these drugs.</li><li>Atenolol — co-administration causes a substantial decrease in sertraline clearance.</li><li>Drugs that prolong the QT interval (such as Class IA and III antiarrhythmics, antipsychotics [phenothiazine derivatives, pimozide, haloperidol], tricyclic antidepressants, certain antimicrobial agents [sparfloxacin, moxifloxacin, erythromycin IV, pentamidine], anti-malaria treatment particularly halofantrine, certain antihistamines [astemizole, mizolastine], and antiretrovirals [such as ritonavir, saquinavir, and lopinavir].<br><p class=\"article-description\" style=\"margin: 0cm 0cm 7.5pt 0cm;\"> </p></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2017d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2017e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2017f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">BNF 75, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2020</a>]</p><!-- end field 1f2e71d9-7e40-460e-9dc9-a91100c51cdb --><!-- end item 9b291b2f-7bd2-47a0-862d-a91100c51ad3 -->","subChapters":[]},{"id":"1cfbedae-acac-52a1-bf5f-60e8f86bd971","slug":"dosing-information","fullItemName":"Dosing Information","depth":3,"htmlHeader":"<!-- begin field cb26a2c2-dd94-490b-aca2-a91100c532bc --><h3>Dosing information</h3><!-- end field cb26a2c2-dd94-490b-aca2-a91100c532bc -->","summary":"","htmlStringContent":"<!-- begin item 54004d2e-5b42-42b6-9ba4-a91100c53212 --><!-- begin field a83ddab3-974c-4c65-82bf-a91100c532bc --><p><strong>Initial dosage and titration of selective serotonin reuptake inhibitors (SSRIs):</strong></p><ul><li><strong>Citalopram (unlicensed):</strong><ul><li>Initial dose 20 mg each day.</li><li>If necessary, increase gradually to a maximum of 40 mg daily (20 mg in the elderly and in those with reduced hepatic function).</li></ul></li><li><strong>Escitalopram:</strong><ul><li>Initial dosage is 10 mg once daily (5 mg once daily in the elderly).</li><li>If necessary, the dose may be increased to a maximum of 20 mg daily (10 mg daily in the elderly).</li></ul></li><li><strong>Fluoxetine:</strong><ul><li>Initial dose 20 mg once a day, in the morning.</li><li>If necessary, increase gradually to a maximum of 60 mg daily.</li></ul></li><li><strong>Fluvoxamine:</strong><ul><li>Initial dose 50 mg once a day, at bedtime.</li><li>Increase to 100 mg, and then gradually in steps of 50 mg to a maximum of 300 mg/day if necessary.</li><li>Usual maintenance dose is 100–300 mg/day (over 150 mg in divided doses).</li></ul></li><li><strong>Paroxetine:</strong><ul><li>Initial dose 20 mg once a day.</li><li>If necessary, increase gradually in steps of 10 mg to 40 mg daily.</li><li>If after some weeks on 40 mg/day an insufficient response is seen, a gradual dose increase up to a maximum of 60 mg/day can be considered.</li></ul></li><li><strong>Sertraline:</strong><ul><li>Initial dose 50 mg once a day, in the morning or evening.</li><li>If necessary, increase gradually in steps of 50 mg to a maximum of 200 mg/day.</li><li>Usual dose range is 50–200 mg daily.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2017d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2017e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2017f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">BNF 75, 2018</a>]</p><!-- end field a83ddab3-974c-4c65-82bf-a91100c532bc --><!-- end item 54004d2e-5b42-42b6-9ba4-a91100c53212 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}